Abeona Therapeutics(US:ABEO)2025-07-02 11:30Financial Transactions - Abeona Therapeutics completed the sale of its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $155 million on June 27, 2025[6]. - As of June 30, 2025, the company's unaudited cash, cash equivalents, restricted cash, and short-term investments totaled approximately $225 million, including net proceeds from the asset sale[8][10]. - The asset sale was executed under a purchase agreement dated May 9, 2025, specifically for the PRV[6]. - The press release regarding the asset sale was issued on July 2, 2025, highlighting the completion of the transaction[8]. Regulatory and Compliance - The Priority Review Voucher was awarded to the company on April 28, 2025, following the approval of its biologics license application for ZEVASKYN™[5]. - The financial information provided is preliminary and subject to completion of the company's financial closing procedures[11]. - The independent registered public accounting firm has not reviewed the preliminary estimates and does not provide any assurance regarding them[11]. - The company plans to file the full text of the PRV Asset Purchase Agreement with its Quarterly Report for the three months ended June 30, 2025[7]. Strategic Initiatives - The asset sale is part of the company's strategy to enhance its financial position and support future growth initiatives[6]. - The company is classified as an emerging growth company under the Securities Act of 1933[4].